AAV-based gene therapies for the muscular dystrophies
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Muscular dystrophy (MD) is a group of progressive genetic diseases affecting the musculature that are characterized by inflammatory infiltrates, necrosis and connective tissue and fat replacement of the affected muscles. Unfortunately, treatments do not exist for the vast majority of MD patients. Adeno-associated viral vector (AAV)-based gene therapy is thus emerging as a potential treatment for many types of MD. Treatments strategies based on AAV are being adapted for replacement of mutant disease-causing genes, knockdown of dominant disease-causing genes using antisense oligonucleotides or inhibitory RNAs, delivery of gene editing tools such as clustered regularly interspaced short palindromic repeats/Cas9 and effecting alterations in pre-mRNA splicing and by manipulating expression levels of modifier genes. Translational and clinical trial work focused on these types of AAV treatments for Duchenne MD, various limb girdle MDs, myotonic dystrophy 1, facioscapulohumeral MD, dysferlinopathies and congenital MDs are discussed here, with a focus on recent studies, pre-clinical large animal work and many promising ongoing and upcoming AAV clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Emery, A. E. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07815-7 · Cited by 1,667 · cited 2×
“muscle has macrophage infiltrates, varying myofiber size, necrosis and muscle fibers replaced with connective tissue and fat (1).”
BackgroundDystrophin Immunity in Duchenne's Muscular Dystrophy
Mendell, J. R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, S., Bowles, D., Gray, S., Li, C., Galloway, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000228 · Cited by 655 · cited 1×
“While clinical trials with microdystrophins are showing promising results, the limited transgene size and threat of an anti-dystrophin immune response (23) have led some groups and companies to pursue alternative strategies.”
BackgroundVery mild muscular dystrophy associated with the deletion of 46% of dystrophin
England, S. B., Nicholson, L. V. B., Johnson, M. A., Forrest, S. M., Love, D. R., Zubrzycka-Gaarn, E. E., Bulman, D. E., Harris, J. B., & Davies, K. E. (1990) · Nature · doi:10.1038/343180a0 · Cited by 623 · cited 1×
“8 kb (7), illustrating that much of the dystrophin protein can be omitted with minimal impact on function.”
BackgroundGene editing restores dystrophin expression in a canine model of Duchenne muscular dystrophy
Amoasii, L., Hildyard, J. C. W., Li, H., Sanchez-Ortiz, E., Mireault, A., Caballero, D., Harron, R., Stathopoulou, T.-R., Massey, C., Shelton, J. M., et al. (2018) · Science · doi:10.1126/science.aau1549 · Cited by 546 · cited 1×
“editing for exon skipping with a single, destructive cut at a splicing acceptor site, as has been successfully done following AAV gene therapy in a canine (44) model of DMD caused by exon 50 deletion.”
MethodCas9 immunity creates challenges for CRISPR gene editing therapies
Crudele, J. M., & Chamberlain, J. S. (2018) · Nature Communications · doi:10.1038/s41467-018-05843-9 · Cited by 259
Self-citationLong-term microdystrophin gene therapy is effective in a canine model of Duchenne muscular dystrophy
Le Guiner, C., Servais, L., Montus, M., Larcher, T., Fraysse, B., Moullec, S., Allais, M., François, V., Dutilleul, M., Malerba, A., et al. (2017) · Nature Communications · doi:10.1038/ncomms16105 · Cited by 246
Cited by
Viral vector platforms within the gene therapy landscape
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L., & Gao, G. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00487-6 · Cited by 1,404
Base editing: advances and therapeutic opportunities
Porto, E. M., Komor, A. C., Slaymaker, I. M., & Yeo, G. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0084-6 · Cited by 476
Innovative Therapeutic Approaches for Duchenne Muscular Dystrophy
Fortunato, F., Rossi, R., Falzarano, M. S., & Ferlini, A. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040820 · Cited by 64
Leray, A., Lalys, P.-A., Varin, J., Bouzelha, M., Bourdon, A., Alvarez-Dorta, D., Pavageau, K., Depienne, S., Marchand, M., Mellet, A., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116148 · Cited by 17
Surrogate gene therapy for muscular dystrophy
Davies, K. E., & Chamberlain, J. S. (2019) · Nature Medicine · doi:10.1038/s41591-019-0604-2 · Cited by 11
Self-citation
Metadata
- Authors
- Crudele, J. M., & Chamberlain, J. S.
- Venue
- Human Molecular Genetics
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-06-25
- Volume
- 28
- Issue
- R1
- Pages
- R102-R107
- ISSN
- 0964-6906 (ISSN-L)
- 1460-2083
- OpenAlex
- W2955318787
- Cited by
- 118
- References
- 6
- FWCI
- 8.53
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AAV-based gene therapies for the muscular dystrophies. https://app.cochat.ai/papers/10.1093/hmg/ddz128
- The paper
- Crudele, J. M., & Chamberlain, J. S. (2019). AAV-based gene therapies for the muscular dystrophies. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddz128
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.